A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa) and BMS-275291 (NSC713763) in Patients With Hormone Refractory Prostate Cancer

Trial Profile

A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa) and BMS-275291 (NSC713763) in Patients With Hormone Refractory Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Rebimastat (Primary) ; Zoledronic acid
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jul 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Planned end date added to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top